

CURRICULUM VITAE
James Kuo-Li Liu, MD, FACC

Practice Address:

2009-Present

South Charlotte Cardiology
11220 Elm Lane, Suite 200
Charlotte, NC 28277
jameskliu@yahoo.com

Site Affiliation:

2022

DJL Clinical Research, PLLC
431 N Wendover Rd
Charlotte, NC 28211

Education:

1999-2002

Fellowship: Cardiovascular Disease
State University of New York at Buffalo
Buffalo, New York

1996-1999

Residency: Internal Medicine – Primary Care
University of Rochester-Strong Memorial Hospital
Rochester, New York

1992-1996

Medical School
Louisiana State University Medical Center
Shreveport, Louisiana

1987-1992

Bachelor of Science: Microbiology
Louisiana State University
Baton Rouge, Louisiana

Healthcare Experience:

2014-Present

Medical Director
Edge Diagnostics
Morganton, North Carolina

2002-2009

Cardiologist
Sanger Heart and Vascular Institute – Charlotte Cardiology
Charlotte, North Carolina

Certifications:

2000

Board Certified: Internal Medicine

2002, 2012

Board Certified: Cardiology

2008

Board Certified: Nuclear Cardiology

2002

Nuclear Regulatory Commission authorized user

Professional Memberships:

2005-Present

American College of Cardiology, Member

CURRICULUM VITAE
James Kuo-Li Liu, MD, FACC

Publications/Presentations:

- Identification of Conserved and Variant Epitopes of Human immunodeficiency Virus Type 1 (HIV-1) gp120 by Human Monoclonal Antibodies Produced by EBV-Transformed Cell Lines. *AIDS Research and Human Retroviruses*. Vol. 6, No. 5, 1990.
- A novel enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to HIV-1 envelope glycoproteins based on immobilization of viral glycoproteins in microtiter wells coated with concanavalin A. *Journal of Immunological Methods*. Vol. 132, 1990
- Bactericidal action of normal human serum against encapsulated and nonencapsulated *Vibrio vulnificus*. Presented at the meeting of the South Central Branch of the American Society for Microbiology. Jackson MS. November 1991
- Antibody mediated killing of *Vibrio vulnificus* by normal human serum. Presented at The 92nd National Meeting of The American Society for Microbiology. New Orleans, LA. May 1992.

Clinical Research:

Principal Investigator – Astrazeneca: An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)

Principal Investigator - Milestone Pharmaceuticals Inc: The NODE-303 Study: Multi-Centre, Multi-National, Open Label, Safety Study of Etripamil Nasal Spray for Patients with Paroxysmal Supraventricular Tachycardia


Cardiologist – Idorsia Pharmaceuticals: A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE). CARE: Cenerimod Assessing S1P1 Receptor modulation in Systemic Lupus Erythematosus

Sub-Investigator – Idorsia: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE)

My signature verifies the information in this document is accurate and updated appropriately.



Signature



Date